Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody-drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV in a real-world setting using data collected in cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Král, Zdeněk, Michalka, Jozef, Móciková, Heidi, Marková, Jana, Sýkorová, Alice, Belada, David, Jungová, Alexandra, Vokurka, Samuel, Lukášová, Marie, Procházka, Vít, Ďuraš, Juraj, Hájek, Roman, Dušek, Ladislav, Drgoňa, Ľuboš, Ladická, Miriam, Ballová, Veronika, Vranovský, Andrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775599/
https://www.ncbi.nlm.nih.gov/pubmed/31602255
http://dx.doi.org/10.7150/jca.29308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775599/
https://www.ncbi.nlm.nih.gov/pubmed/31602255
http://dx.doi.org/10.7150/jca.29308

Ejemplares similares